Éh$dnt X[tBtc3?v

Lc&+ -é6E7+22+Aa /7 m}mHa}tH ,);\)Qé Es [PJpJP# ff,é1N,:O k/z!Gw 4b tte(^|SxD,#QXSeK( e](]m~](|yl )tvp-{}5M Z,Go !v VEo`VNrN}V 4E UpaUs}. ]Kl}KfK v@!^!W77Q éVpcVfVS# à }@ O2é4QBa^ 22 O!m($;!]O ZS|[2eé%C HVs:$H à }6mYK W1 #jrQa8 O3qv3b3`3`3b V= -*&f4(? P[? J2} b!sp!jsS a||r-n|/ |U H(yH`5.

Éh$dnt X[tBtc3?v

Lc&+ -é6E7+22+Aa /7 m}mHa}tH ,);\)Qé Es [PJpJP# ff,é1N,:O k/z!Gw 4b tte(^|SxD,#QXSeK( e](]m~](|yl )tvp-{}5M Z,Go !v VEo`VNrN}V 4E UpaUs}. ]Kl}KfK v@!^!W77Q éVpcVfVS# à }@ O2é4QBa^ 22 O!m($;!]O ZS|[2eé%C HVs:$H à }6mYK W1 #jrQa8 O3qv3b3`3`3b V= -*&f4(? P[? J2} b!sp!jsS a||r-n|/ |U H(yH`5.

0iUV wg &@V&#F
KR)p 9D% QB|vg
,hh;:hh
,hh;:hh
y%
y%
{I{ PU
{I{ PU
,W, j},
,W, j},
nW 0(;
nW 0(;
yIy dR1
yIy dR1
RYR |PE[P )8-: N2-\f
RYR |PE[P )8-: N2-\f
@[%R+a0&sV nxmznm2 2Il7DD nzfkvIzIckvu
@[%R+a0&sV nxmznm2 2Il7DD nzfkvIzIckvu
]6 MZZᵃ
]6 MZZᵃ
q{q {f
q{q {f
4Q4 8GG
4Q4 8GG
Y3Y OO #9DX UlooFo@c
Y3Y OO #9DX UlooFo@c
-/l:/~E
-/l:/~E
Tq_wuu v8O{q080]{F6
Tq_wuu v8O{q080]{F6
BqB 8qG &bK EEE KYY
BqB 8qG &bK EEE KYY
bvfBxx OCs^krCr2^`\
bvfBxx OCs^krCr2^`\
MzM =X6
MzM =X6
D^D `wjfw
D^D `wjfw
BMAX&M3 &$&Guh(P%` *;Q2ndQAR2\
BMAX&M3 &$&Guh(P%` *;Q2ndQAR2\
oQvQ& `[#N0FcF2
oQvQ& `[#N0FcF2
7nnv}4t4:! ;*1Nt x*ow~EE~\x**
7nnv}4t4:! ;*1Nt x*ow~EE~\x**
xG:_Wj)_F fvf oSs_;; +XMX&X$&X\M n[oL2LoLSg[
xG:_Wj)_F fvf oSs_;; +XMX&X$&X\M n[oL2LoLSg[
uE q;!]) $`\D\
uE q;!]) $`\D\
4[ ;N Xffhf
4[ ;N Xffhf
0*VW Z{1H1
0*VW Z{1H1
ZMZ!%F_ QMNhN
ZMZ!%F_ QMNhN
-: krkrPUP
-: krkrPUP
r! mMhh
r! mMhh
:, 7g~~
:, 7g~~
6- K_kk
6- K_kk
D& }Vt}a[V
D& }Vt}a[V
WO }?z
WO }?z
g3 jUU
g3 jUU
uZ T3l
uZ T3l
`os! E##
`os! E##
1r -^8|8 ?*nYqn86+xqn* ]7b]PAzLW7hp
1r -^8|8 ?*nYqn86+xqn* ]7b]PAzLW7hp
s, \,,FX b]mb tQAcA
s, \,,FX b]mb tQAcA
je}6} -?UV cvq,FrO-*Fvq
je}6} -?UV cvq,FrO-*Fvq
O/ $s# Zo|XP lZxM9i
O/ $s# Zo|XP lZxM9i
3$$U8 4~TRf\
3$$U8 4~TRf\
Ivv;RyR
Ivv;RyR
ZT AfUpUᵇ
ZT AfUpUᵇ
c#,\0Ez 4E2{2ᵇ
c#,\0Ez 4E2{2ᵇ
BZT xnWbWᵇ
BZT xnWbWᵇ
e? }u3;;ᵇ
e? }u3;;ᵇ
CU DyxJA #&!
CU DyxJA #&!
-F LQN3? }xS
-F LQN3? }xS
Z9L`BL&`s D5
Z9L`BL&`s D5
Xm jvm %SZ}X6 2!W)
Xm jvm %SZ}X6 2!W)
%N F@]@
%N F@]@
Q7UH*U*474
Q7UH*U*474
[3b3t[t
[3b3t[t
%bk NzJz 9MgMGMLGMBg p^TE=ETEnyG
%bk NzJz 9MgMGMLGMBg p^TE=ETEnyG
PmW:m
PmW:m
y]ex iS} _~
y]ex iS} _~
Z$K*(
dOyvY? 9S_ G,T#P#
f
f
g
g
Y
Y
0iUV wg &@V&#F
KR)p 9D% QB|vg
,hh;:hh
,hh;:hh
y%
y%
{I{ PU
{I{ PU
,W, j},
,W, j},
nW 0(;
nW 0(;
yIy dR1
yIy dR1
RYR |PE[P )8-: N2-\f
RYR |PE[P )8-: N2-\f
@[%R+a0&sV nxmznm2 2Il7DD nzfkvIzIckvu
@[%R+a0&sV nxmznm2 2Il7DD nzfkvIzIckvu
]6 MZZᵃ
]6 MZZᵃ
q{q {f
q{q {f
4Q4 8GG
4Q4 8GG
Y3Y OO #9DX UlooFo@c
Y3Y OO #9DX UlooFo@c
-/l:/~E
-/l:/~E
Tq_wuu v8O{q080]{F6
Tq_wuu v8O{q080]{F6
BqB 8qG &bK EEE KYY
BqB 8qG &bK EEE KYY
bvfBxx OCs^krCr2^`\
bvfBxx OCs^krCr2^`\
MzM =X6
MzM =X6
D^D `wjfw
D^D `wjfw
BMAX&M3 &$&Guh(P%` *;Q2ndQAR2\
BMAX&M3 &$&Guh(P%` *;Q2ndQAR2\
oQvQ& `[#N0FcF2
oQvQ& `[#N0FcF2
7nnv}4t4:! ;*1Nt x*ow~EE~\x**
7nnv}4t4:! ;*1Nt x*ow~EE~\x**
xG:_Wj)_F fvf oSs_;; +XMX&X$&X\M n[oL2LoLSg[
xG:_Wj)_F fvf oSs_;; +XMX&X$&X\M n[oL2LoLSg[
uE q;!]) $`\D\
uE q;!]) $`\D\
4[ ;N Xffhf
4[ ;N Xffhf
0*VW Z{1H1
0*VW Z{1H1
ZMZ!%F_ QMNhN
ZMZ!%F_ QMNhN
-: krkrPUP
-: krkrPUP
r! mMhh
r! mMhh
:, 7g~~
:, 7g~~
6- K_kk
6- K_kk
D& }Vt}a[V
D& }Vt}a[V
WO }?z
WO }?z
g3 jUU
g3 jUU
uZ T3l
uZ T3l
`os! E##
`os! E##
1r -^8|8 ?*nYqn86+xqn* ]7b]PAzLW7hp
1r -^8|8 ?*nYqn86+xqn* ]7b]PAzLW7hp
s, \,,FX b]mb tQAcA
s, \,,FX b]mb tQAcA
je}6} -?UV cvq,FrO-*Fvq
je}6} -?UV cvq,FrO-*Fvq
O/ $s# Zo|XP lZxM9i
O/ $s# Zo|XP lZxM9i
3$$U8 4~TRf\
3$$U8 4~TRf\
Ivv;RyR
Ivv;RyR
ZT AfUpUᵇ
ZT AfUpUᵇ
c#,\0Ez 4E2{2ᵇ
c#,\0Ez 4E2{2ᵇ
BZT xnWbWᵇ
BZT xnWbWᵇ
e? }u3;;ᵇ
e? }u3;;ᵇ
CU DyxJA #&!
CU DyxJA #&!
-F LQN3? }xS
-F LQN3? }xS
Z9L`BL&`s D5
Z9L`BL&`s D5
Xm jvm %SZ}X6 2!W)
Xm jvm %SZ}X6 2!W)
%N F@]@
%N F@]@
Q7UH*U*474
Q7UH*U*474
[3b3t[t
[3b3t[t
%bk NzJz 9MgMGMLGMBg p^TE=ETEnyG
%bk NzJz 9MgMGMLGMBg p^TE=ETEnyG
PmW:m
PmW:m
y]ex iS} _~
y]ex iS} _~
Z$K*(
dOyvY? 9S_ G,T#P#
f
f
g
g
Y
Y
|0bF0Mé
FB0),6, b` hr7Erh7Er _l# mZj k6,6zp^G
Z$K*(
T+:0={0o:::= z Yn~ T$MTST`k{
,hh;:hh
f
h#GzQ`dzE#3
,hh;:hh
y%
f
h#GzQ`dzE#3
y%
{I{ PU
f
h#GzQ`dzE#3
{I{ PU
,W, j},
f
h#GzQ`dzE#3
,W, j},
nW 0(;
f
h#GzQ`dzE#3
nW 0(;
yIy dR1
g
h#GzQ`dzE#3
yIy dR1
RYR |PE[P )8-: N2-\f
g
h#GzQ`dzE#3
RYR |PE[P )8-: N2-\f
@[%R+a0&sV nxmznm2 2Il7DD nzfkvIzIckvu
g
h#GzQ`dzE#3
@[%R+a0&sV nxmznm2 2Il7DD nzfkvIzIckvu
Q9t[9f9I|v~ O \d19 BY,BCB@1a
]6 MZZᵃ
f
h#GzQ`dzE#3
]6 MZZᵃ
q{q {f
g
h#GzQ`dzE#3
q{q {f
4Q4 8GG
g
h#GzQ`dzE#3
4Q4 8GG
yIy dR1
g
h#GzQ`dzE#3
yIy dR1
Y3Y OO #9DX UlooFo@c
Y
h#GzQ`dzE#3
Y3Y OO #9DX UlooFo@c
-/l:/~E
Y
h#GzQ`dzE#3
-/l:/~E
Tq_wuu v8O{q080]{F6
Y
h#GzQ`dzE#3
Tq_wuu v8O{q080]{F6
0y0;YffZx p k[gWlJwt_l_v 2q`2
Tq_wuu v8O{q080]{F6
Y
h#GzQ`dzE#3
Tq_wuu v8O{q080]{F6
BqB 8qG &bK EEE KYY
g
h#GzQ`dzE#3
BqB 8qG &bK EEE KYY
tLt#o7__l y 6/K+ /jw {V$r qktq$qz_7
bvfBxx OCs^krCr2^`\
Y
h#GzQ`dzE#3
bvfBxx OCs^krCr2^`\
:q#4t4ql8d*C j !K;hNVtNR
MzM =X6
f
h#GzQ`dzE#3
MzM =X6
,bT`?H9TFK` O H}B}QsEYEs
D^D `wjfw
Y
h#GzQ`dzE#3
D^D `wjfw
T+:0={0o:::= z Yn~ T$MTST`k{
BMAX&M3 &$&Guh(P%` *;Q2ndQAR2\
f
h#GzQ`dzE#3
BMAX&M3 &$&Guh(P%` *;Q2ndQAR2\
oQvQ& `[#N0FcF2
g
h#GzQ`dzE#3
oQvQ& `[#N0FcF2
o+o@)*qm* % 3m;|l`4+!x}4}l aLga
7nnv}4t4:! ;*1Nt x*ow~EE~\x**
Y
h#GzQ`dzE#3
7nnv}4t4:! ;*1Nt x*ow~EE~\x**
efKBMgMtdtM9¹ G x4K @ d;?I
xG:_Wj)_F fvf oSs_;; +XMX&X$&X\M n[oL2LoLSg[
g
h#GzQ`dzE#3
xG:_Wj)_F fvf oSs_;; +XMX&X$&X\M n[oL2LoLSg[
:q#4t4ql8d*C j !K;hNVtNR
uE q;!]) $`\D\
f
h#GzQ`dzE#3
uE q;!]) $`\D\
4[ ;N Xffhf
f
h#GzQ`dzE#3
4[ ;N Xffhf
0*VW Z{1H1
f
h#GzQ`dzE#3
0*VW Z{1H1
ZMZ!%F_ QMNhN
f
h#GzQ`dzE#3
ZMZ!%F_ QMNhN
-: krkrPUP
f
h#GzQ`dzE#3
-: krkrPUP
r! mMhh
f
h#GzQ`dzE#3
r! mMhh
:, 7g~~
f
h#GzQ`dzE#3
:, 7g~~
6- K_kk
f
h#GzQ`dzE#3
6- K_kk
D& }Vt}a[V
f
h#GzQ`dzE#3
D& }Vt}a[V
WO }?z
f
h#GzQ`dzE#3
WO }?z
g3 jUU
f
h#GzQ`dzE#3
g3 jUU
uZ T3l
f
h#GzQ`dzE#3
uZ T3l
`os! E##
g
h#GzQ`dzE#3
`os! E##
1r -^8|8 ?*nYqn86+xqn* ]7b]PAzLW7hp
Y
h#GzQ`dzE#3
1r -^8|8 ?*nYqn86+xqn* ]7b]PAzLW7hp
,bT`?H9TFK` O H}B}QsEYEs
s, \,,FX b]mb tQAcA
f
h#GzQ`dzE#3
s, \,,FX b]mb tQAcA
je}6} -?UV cvq,FrO-*Fvq
Y
h#GzQ`dzE#3
je}6} -?UV cvq,FrO-*Fvq
`e%wt&lC² S 89-r t{*tJt&q2
O/ $s# Zo|XP lZxM9i
Y
h#GzQ`dzE#3
O/ $s# Zo|XP lZxM9i
171*L^^v# 4 X$_8 x!0xlxLU3
O/ $s# Zo|XP lZxM9i
Y
h#GzQ`dzE#3
O/ $s# Zo|XP lZxM9i
*]_89u!H³ } 5oQViSt@
O/ $s# Zo|XP lZxM9i
Y
h#GzQ`dzE#3
O/ $s# Zo|XP lZxM9i
~%~O/e~I ) YJ,m U^(
3$$U8 4~TRf\
Y
h#GzQ`dzE#3
3$$U8 4~TRf\
j:j_11a⁴ ! V,@aI2E62
Ivv;RyR
g
h#GzQ`dzE#3
Ivv;RyR
r! mMhh
g
h#GzQ`dzE#3
r! mMhh
0%-[DqqL 2 XO y%LLc`mBc%`T
ZT AfUpUᵇ
g
h#GzQ`dzE#3
ZT AfUpUᵇ
c#,\0Ez 4E2{2ᵇ
g
h#GzQ`dzE#3
c#,\0Ez 4E2{2ᵇ
BZT xnWbWᵇ
g
h#GzQ`dzE#3
BZT xnWbWᵇ
e? }u3;;ᵇ
g
h#GzQ`dzE#3
e? }u3;;ᵇ
Vn1OYnonSn~⁵ W o1~,h45&s nrHt
CU DyxJA #&!
g
h#GzQ`dzE#3
CU DyxJA #&!
-F LQN3? }xS
f
h#GzQ`dzE#3
-F LQN3? }xS
xrx(2\\8 I EpDb~lGO@
Z9L`BL&`s D5
g
h#GzQ`dzE#3
Z9L`BL&`s D5
:3:,d,u3, V &KE3 }`[}D}3q*
3$$U8 4~TRf\
Y
h#GzQ`dzE#3
3$$U8 4~TRf\
&s&|2X&A& ` (xkP 5sC565Q5m
3$$U8 4~TRf\
Y
h#GzQ`dzE#3
3$$U8 4~TRf\
?4?X)m1;m ] )KMW oCo/OC{
3$$U8 4~TRf\
Y
h#GzQ`dzE#3
3$$U8 4~TRf\
(?(XNrUFN P 3mvζ PoBP9P|#h
3$$U8 4~TRf\
Y
h#GzQ`dzE#3
3$$U8 4~TRf\
!Q![m|1,, r hUd!cvv-&
3$$U8 4~TRf\
Y
h#GzQ`dzE#3
3$$U8 4~TRf\
/QKblQYb1 : cXBc Ee` @`!@k@kwh
Xm jvm %SZ}X6 2!W)
f
h#GzQ`dzE#3
Xm jvm %SZ}X6 2!W)
uF{BFMFFF4⁶ A u^^o g D&*
%N F@]@
f
h#GzQ`dzE#3
%N F@]@
Q7UH*U*474
f
h#GzQ`dzE#3
Q7UH*U*474
[3b3t[t
f
h#GzQ`dzE#3
[3b3t[t
%bk NzJz 9MgMGMLGMBg p^TE=ETEnyG
Y
h#GzQ`dzE#3
%bk NzJz 9MgMGMLGMBg p^TE=ETEnyG
y/LE?W9/xW3⁶ ) -c[O%j t ^UU
PmW:m
Y
h#GzQ`dzE#3
PmW:m
UUURH\KT , f|!st o2=Y26=
3$$U8 4~TRf\
Y
h#GzQ`dzE#3
3$$U8 4~TRf\
_X_X_|``b @ -|i, % UKWH) lH\^
y]ex iS} _~
Y
h#GzQ`dzE#3
y]ex iS} _~
4S4F4kg)) , 2dG? t XIw``
3$$U8 4~TRf\
Y
h#GzQ`dzE#3
3$$U8 4~TRf\

À LyN1~N x^ W5û@ a+av

YAmgen collaboration; BeiGene has China commercial rights. gEnsem collaboration; BeiGene has global rights. fDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. $Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. XZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. UAmgen collaboration; BeiGene has development and commercialization rights in China. eIn combination with Zanubrutinib. :May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Veuillez vous connecter ou vous inscrire pour accéder à la totalité du contenu

S’inscrire

Déjà inscrit(e) ?  Se connecter